Oceanside maker of COVID-19 drug says it will cost about $3,000 per patient – FOX 5 San Diego

thumbnail

The Trump administration has actually stockpiled half a million courses of Remdesivir treatment for circulation to medical facilities around the country.

Remdesivir is approved just for patients who are seriously ill. It is administered intravenously, and it is the only drug that has an emergency usage authorization from the Food and Drug Adminisration to treat coronavirus infections.

According to experts in this field, the price set by Gilead is equivalent with the cost of other ICU drugs. Compared to the cheap and widely readily available corticosteroid dexamethasone, which costs a few dollars a day and is revealing simply as much guarantee for COVID treatment, Remdesivir is a lot more costly.

OCEANSIDE, Calif.– The Oceanside business that makes the COVID-19 drug Remdesivir announced Monday the rate for the drug moving on.

Gilead Sciences said a single dose of Remdesivir will cost $390. A common course of treatment needs 6 vials administered over 5 days in the intensive care unit of a medical facility. That means a typical five-day treatment will cost $2,340 per patient. That rate is only offered to the United States government, which is handling distribution to hospitals briefly due to the lack of schedule. For patients covered by personal insurance coverage, the cost will jump to $520 per vial, which adds up to $3,120 per client– practically a thousand dollars more.

Gilead CEO Daniel O’Day issued a letter detailing the business’s choice. It checks out in part, “As with all our actions on Remdesivir, we approached this with the objective of assisting as lots of patients as possible, as rapidly as possible and in the most responsible way. This has actually been our compass point throughout, from collaborating to find fast answers on safety and effectiveness, to scaling up production and donating our supply of Remdesivir through completion of June. In each case, we acknowledged the need to do things in a different way to reflect the extraordinary scenarios of the pandemic. now, as we shift beyond the contribution duration and set a cost for Remdesivir, the very same principle uses.”